ライフサイエンスコーパス: histone deacetylase inhibitor

1 th suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor.

2 tructurally unique, potent class 1 selective histone deacetylase inhibitor.

3 ght potentially benefit from the use of this histone deacetylase inhibitor.

4 lation and mimicked by trichostatin A, a pan-histone deacetylase inhibitor.

5 n as chidamide) is an oral subtype-selective histone deacetylase inhibitor.

6 Panobinostat (pano) is an FDA-approved histone deacetylase inhibitor.

7 howcased by the formal synthesis of a potent histone deacetylase inhibitor.

8 disruption of the human Sin3 network with a histone deacetylase inhibitor.

9 bination of PI3K-alpha/delta inhibitors with histone deacetylase inhibitors.

10 -1beta in the absence or presence of various histone deacetylase inhibitors.

11 ated transcription factor regulators such as histone deacetylase inhibitors.

12 ensitivity to epigenetic modulators, such as histone deacetylase inhibitors.

13 fied these seleno-alpha-keto acids as potent histone deacetylase inhibitors.

14 hydroxamates (2) and 2-aminoanilides (3) as histone deacetylase inhibitors.

15 otypes can be partially rescued with certain histone deacetylase inhibitors.

16 agents, including ultraviolet radiation and histone deacetylase inhibitors.

17 sor effects are globally similar to those of histone deacetylase inhibitors.

18 gene expression alone or in combination with histone deacetylase inhibitors.

19 ndoles has been identified as a new class of histone deacetylase inhibitors.

20 death in CTCL especially when combined with histone deacetylase inhibitors.

21 ions had the highest level of sensitivity to histone deacetylase inhibitors.

22 d increased sensitivity of leukemia cells to histone deacetylase inhibitors.

23 that RAE-1 is transcriptionally repressed by histone deacetylase inhibitor 3 (HDAC3) in healthy cells

24 These molecules include histone deacetylase inhibitors, 4-phenylbutyrate (4PBA)

25 that uses low-dose DNA methyltransferase and histone deacetylase inhibitors, 5-azacytidine and entino

26 Indeed, treatment with novel histone deacetylase inhibitors abolished hypoxia-induced

27 using Bruton's tyrosine kinase inhibitor and histone deacetylase inhibitor abrogated refractory B-1b

28 SAMHD1-dependent antiretroviral activity of histone deacetylase inhibitors acting via p53 activation

29 in A, and two small molecules without direct histone deacetylase inhibitor activity, hydroxyurea (HU)

30 ed to virus production by a combination of a histone deacetylase inhibitor and a protein kinase C act

31 nt epigenetic modulators and identified four histone deacetylase inhibitors and a bromodomain and ext

32 We further observed strong synergy between histone deacetylase inhibitors and EZH2 inhibitors.

33 menable to pharmacological intervention with histone deacetylase inhibitors and help to explain the b

34 Based on the synergism between histone deacetylase inhibitors and hypomethylating agent

35 , combinations of proteasome inhibitors with histone deacetylase inhibitors and ixabepilone and MK177

36 azole and its analogues are isoform-targeted histone deacetylase inhibitors and potent LRAs.

37 and can be re-activated with Trichostatin A (histone deacetylase inhibitor) and/or 5-aza-dC (an inhib

38 erferon alpha, extracorporeal photopheresis, histone deacetylase inhibitors, and antibody therapies s

39 poptotic triggers, including glucocorticoid, histone deacetylase inhibitors, and overexpression of th

40 at suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor approved for cancer treatm

41 Romidepsin is a histone deacetylase inhibitor approved for the treatment

42 Belinostat (BEL), a histone deacetylase inhibitor approved for the treatment

43 Histone deacetylase inhibitors are currently approved to

44 st HDACi pharmacological activity.IMPORTANCE Histone deacetylase inhibitors are widely studied HIV la

45 with Akt, mammalian target of rapamycin, or histone deacetylase inhibitors, are active even in borte

46 ted in humans, provides proof-of-concept for histone deacetylase inhibitors as a therapeutic class, a

47 cacy and tolerability of belinostat, a novel histone deacetylase inhibitor, as a single agent in rela

48 HA), a Food and Drug Administration-approved histone deacetylase inhibitor, as an enhancer of GRN exp

49 cells could be induced into lytic phase with histone deacetylase inhibitors, as is known for latently

50 identifies cell types that are sensitive to histone deacetylase inhibitors based on their metabolic

51 ng histone acetylation via administration of histone deacetylase inhibitors before or after a learnin

52 beta receptor II (TGFbetaRII) induced by the histone deacetylase inhibitor belinostat, we observed re

53 her known P-TEFb-releasing agents, including histone deacetylase inhibitors, bromodomain and extrater

54 redict that combinations of standard agents, histone deacetylase inhibitors, bromodomain inhibitors,

55 sting primed hESC lines by preculture in the histone deacetylase inhibitors butyrate and suberoylanil

56 intact high-H3K27me3 levels; treatment with histone deacetylase inhibitors can relieve chromatin com

57 by a variety of anti-cancer drugs, including histone deacetylase inhibitors, confers chemoresistance

58 at the combination of an ACE inhibitor and a histone deacetylase inhibitor could have therapeutic pot

59 agents (IMiDs), proteasome inhibitors (PIs), histone deacetylase inhibitors (DACIs), and monoclonal a

60 Panobinostat, a histone deacetylase inhibitor, demonstrated potent activ

61 d 3' genetic elements and sublethal doses of histone deacetylase inhibitors demonstrates that while t

62 Histone deacetylase inhibitors (DIs) are promising drugs

63 been proposed for DNA methyltransferase and histone deacetylase inhibitors (DNMTi and HDACi), primar

64 relevant doses of DNA methyltransferase and histone deacetylase inhibitors (DNMTi and HDACi, respect

65 Here, we show that the histone deacetylase inhibitor drug, vorinostat, in addit

66 fic overexpression of Ascl1, together with a histone deacetylase inhibitor, enables adult mice to gen

67 Previously known functions include histone deacetylase inhibitor, endoplasmic reticulum str

68 Trichostatin A (TSA), a histone deacetylase inhibitor, enhanced ENaC acetylation

69 s reason, we investigated the ability of the histone deacetylase inhibitor entinostat (ENT) to trigge

70 eage of origin, which led us to identify the histone deacetylase inhibitor entinostat as a pharmacolo

71 of the retinoic acid receptor (RAR)-beta The histone deacetylase inhibitor entinostat is emerging as

72 ved by combining EHMT1/2 inhibition with the histone deacetylase inhibitor entinostat or hypomethylat

73 Here we report that combining the histone deacetylase inhibitor entinostat with the demeth

74 al organs, whereas a combination of PAD4 and histone deacetylase inhibitors further decreases tumor g

75 n line with this finding, treatment with the histone deacetylase inhibitor givinostat caused a signif

76 The development of clinically useful histone deacetylase inhibitors has expanded greatly.

77 In some cases, the therapeutic effects of histone deacetylase inhibitors have been attributed to a

78 Histone deacetylase inhibitors have been demonstrated to

79 For more than a decade now, histone deacetylase inhibitors have been investigated fo

80 Histone deacetylase inhibitors have shown some activity

81 Treatment of mice with the histone deacetylase inhibitor (HDAC-I) vorinostat restor

82 molecular response to one such intervention, histone deacetylase inhibitor (HDACi) administration.

83 n agent that promotes chromatin opening, the histone deacetylase inhibitor (HDACi) AR-42, ameliorates

84 olated from ART-suppressed patients with the histone deacetylase inhibitor (HDACi) panobinostat toget

85 that treatment with the anticancer compounds histone deacetylase inhibitor (HDACi) results in a profo

86 The histone deacetylase inhibitor (HDACi) sodium butyrate pr

87 The therapeutic potential of histone deacetylase inhibitor (HDACi) treatment has attr

88 We now show that the FDA-approved histone deacetylase inhibitor (HDACi) valproic acid (VPA

89 In this study romidepsin, a potent histone deacetylase inhibitor (HDACi), induced apoptosis

90 Treating differentiating osteoblasts with histone deacetylase inhibitors (HDACi) abrogated their a

91 Finally, we discovered how histone deacetylase inhibitors (HDACi) alone, when admin

92 ased on the well-established synergy between histone deacetylase inhibitors (HDACi) and alkylating ag

93 roylanilide hydroxamic acid (vorinostat) are histone deacetylase inhibitors (HDACi) approved by the U

94 Histone deacetylase inhibitors (HDACi) are being evaluat

95 Controversially, histone deacetylase inhibitors (HDACi) are in clinical t

96 Histone deacetylase inhibitors (HDACi) are largely ineff

97 Histone deacetylase inhibitors (HDACi) are the most wide

98 ing a chemical library screen, we identified histone deacetylase inhibitors (HDACi) as agents reducin

99 egulated upon treatment with pan- or class I histone deacetylase inhibitors (HDACi) as well as after

100 We describe a set of novel histone deacetylase inhibitors (HDACi) equipped with eit

101 an TTNT of 8.7 months (95% CI 6.0-18.0), and histone deacetylase inhibitors (HDACi) gave a median TTN

102 Histone deacetylase inhibitors (HDACi) have been propose

103 Histone deacetylase inhibitors (HDACi) have been shown t

104 Histone deacetylase inhibitors (HDACi) have been suggest

105 s, we identified miR-31 as a novel target of histone deacetylase inhibitors (HDACi) in breast cancer

106 previously showed that 2-aminobenzamide-type histone deacetylase inhibitors (HDACi) increase FXN mRNA

107 Clinical response to histone deacetylase inhibitors (HDACi) is strongly assoc

108 estigate this notion, we tested 24 different histone deacetylase inhibitors (HDACi) on colon cancer c

109 reactivation of dormant HIV-1 proviruses by histone deacetylase inhibitors (HDACi) represents a poss

110 Treatment with histone deacetylase inhibitors (HDACI) results in potent

111 Histone deacetylase inhibitors (HDACi) target abnormal e

112 ing group (ZBG) have been the most effective histone deacetylase inhibitors (HDACi) to date.

113 Clinical trials investigating histone deacetylase inhibitors (HDACi) to reverse HIV-1

114 By using a "drug repurposing" strategy, histone deacetylase inhibitors (HDACi), which are presen

115 efforts has been on a class of drugs called histone deacetylase inhibitors (HDACi), which have the p

116 ch as molecularly targeted agents, including histone deacetylase inhibitors (HDACi).

117 that these were similar to those induced by histone deacetylase inhibitors (HDACi).

118 proposed as the major antitumor responses to histone deacetylase inhibitors (HDACi).

119 s inhibited by valproic acid (VPA) and other histone deacetylase inhibitors (HDACi).

120 5) inhibited tail regeneration, including 18 histone deacetylase inhibitors (HDACi).

121 to fitness of the individual in response to histone deacetylases inhibitors (HDACi).

122 Histone deacetylase inhibitors (HDACIs) activate the pro

123 ies include PKC and MAPK agonists as well as histone deacetylase inhibitors (HDACis) and bromodomain

124 Interactions between histone deacetylase inhibitors (HDACIs) and decitabine w

125 s on CD8+ T cell phenotype and function: the histone deacetylase inhibitors (HDACis) and protein kina

126 one methyltransferase inhibitors (HMTis) and histone deacetylase inhibitors (HDACis) are reported to

127 d progression that prompt the development of histone deacetylase inhibitors (HDACIs) as anticancer ag

128 Histone deacetylase inhibitors (HDACIs) can disrupt the

129 In this study, we show that histone deacetylase inhibitors (HDACIs) can inhibit apop

130 We presently demonstrate that histone deacetylase inhibitors (HDACIs) enhance toxicity

131 Histone deacetylase inhibitors (HDACis) have been shown

132 methyltransferase inhibitors [DNMTis]) with histone deacetylase inhibitors (HDACis) holds promise fo

133 rated that in malignant hematopoietic cells, histone deacetylase inhibitors (HDACIs) induced RelA hyp

134 n the present study, we investigated whether histone deacetylase inhibitors (HDACis) may induce a fav

135 Histone deacetylase inhibitors (HDACIs) may overcome end

136 It has been suggested that histone deacetylase inhibitors (HDACis) may purge HIV in

137 Recent evidence suggests histone deacetylase inhibitors (HDACis) may represent a

138 merous studies have looked at the effects of histone deacetylase inhibitors (HDACis) on HIV reactivat

139 We found that histone deacetylase inhibitors (HDACis) significantly in

140 In vivo studies have shown histone deacetylase inhibitors (HDACis) to be neuroprote

141 We showed previously that the histone deacetylase inhibitors (HDACIs) trichostatin A a

142 ced by AML1-ETO-targeting drugs, such as the histone deacetylase inhibitors (HDACis) valproic acid (V

143 Several histone deacetylase inhibitors (HDACIs) were used in vit

144 SDHB protein increased after treatment with histone deacetylase inhibitors (HDACis), implicating the

145 Among the most effective compounds were histone deacetylase inhibitors (HDACIs).

146 dividing CB CD34+ cells ex vivo with several histone deacetylase inhibitors (HDACIs).

147 0 antibodies and confirmed with nonselective histone deacetylase inhibitors (HDACis).

148 To identify molecular determinants of histone deacetylase inhibitor (HDI) resistance, we selec

149 Histone deacetylase inhibitors (HDI) have exhibited some

150 Histone deacetylase inhibitors (HDIs) promote terminal o

151 ndicating a potential therapeutic benefit of histone deacetylase inhibitors (HDIs), and preclinical d

152 In fact, two histone deacetylase inhibitors (HDIs), SAHA and Depsipep

153 rogression is suppressed by treatment with a histone deacetylase inhibitor; however, this treatment h

154 histone deacetylases; a screen for suitable histone deacetylase inhibitors identified belinostat as

155 ected pharmaceutical residues in water, is a histone deacetylase inhibitor in mammals, and is reporte

156 on, which can be reactivated by a mixture of histone deacetylase inhibitors in combination with TNF.

157 used for measurement of cellular potency of histone deacetylase inhibitors in intact cells.

158 ne perturbations could reduce sensitivity to histone deacetylase inhibitors in SS patients.

159 Histone deacetylase inhibitors, including valproic acid,

160 identified the molecular mechanism by which histone deacetylase inhibitors increase the quantity and

161 Histone deacetylase inhibitors induce apoptosis and re-e

162 sing a high-throughput screen, we found that histone deacetylase inhibitors induce Id2 expression by

163 We also showed that AR-42, a pan-histone deacetylase inhibitor, inhibited proliferation o

164 We found that bilateral infusions of a histone deacetylase inhibitor into the CeA attenuated an

165 Panobinostat (a pan histone deacetylase inhibitor) is approved in combinatio

166 Valproic acid (VPA), an histone deacetylase inhibitor, is emerging as a promisin

167 Upon treatment with histone deacetylase inhibitors, KSHV-infected murine cel

168 atment of BALB/c murine macrophages with the histone deacetylase inhibitor LAQ824 induces chromatin c

169 The histone deacetylase inhibitor largazole 1 was synthesize

170 A number of analogues of the marine-derived histone deacetylase inhibitor largazole incorporating ma

171 A2, or suppressing HMGA2 expression with the histone deacetylase inhibitor LBH589, inhibits epithelia

172 ed with treatment of melanoma cells with the histone deacetylase inhibitor LBH589.

173 oylanilide hydroxamic acid (SAHA), and other histone deacetylase inhibitors lead to a rapid release o

174 Nevertheless, derepression of frataxin by a histone deacetylase inhibitor leads to a decrease in miR

175 combination of a demethylating reagent and a histone deacetylase inhibitor led to rapid activation of

176 Notably, pan-histone deacetylase inhibitors lift promoter-specific re

177 We show that the small-molecule histone deacetylase inhibitor M344 reduces beta-amyloid

178 etic changes and that valproic acid (VPA), a histone deacetylase inhibitor, may reverse such changes.

179 The selectivity of histone deacetylase inhibitor-mediated silencing of AICD

180 are a prerequisite during the cell cycle and histone deacetylase inhibitor-mediated therapeutics.

181 compound identified from this screen was the histone deacetylase inhibitor methyl-4-(phenylthio)butan

182 ities incorporating antifolates, conjugates, histone deacetylase inhibitors, monoclonal antibodies, n

183 genes and prevented by administration of the histone deacetylase inhibitor MS-275.

184 A histone deacetylase inhibitor, MS-275, resulted in upreg

185 with extinction enhancements induced by the histone deacetylase inhibitor NaB.

186 One histone deacetylase inhibitor, NCH-51, was validated as

187 Preclinical studies have shown that the histone deacetylase inhibitor nicotinamide (vitamin B3)

188 NS and has several advantages over available histone deacetylase inhibitors now in clinical trials, o

189 egulation and demonstrate a direct effect of histone deacetylase inhibitors on the SS18-SSX complex c

190 Accordingly, histone deacetylase inhibitors or BET inhibitors, the la

191 Treatment with histone deacetylase inhibitors or depletion of the polyc

192 ination with other epigenetic drugs, such as histone deacetylase inhibitors or differentiation induce

193 scent HSPCs are resistant to reactivation by histone deacetylase inhibitors or P-TEFb activation but

194 Cotreatment with BA and panobinostat (pan-histone deacetylase inhibitor) or palbociclib (CDK4/6 in

195 compared with interferon-alpha (P = .0067), histone deacetylase inhibitors (P = .0003), novel immuno

196 The multi-histone deacetylase inhibitor panobinostat demonstrated

197 to determine the safety and activity of the histone deacetylase inhibitor panobinostat in patients w

198 e CDK7/super-enhancer inhibitor THZ1 and the histone deacetylase inhibitor panobinostat synergistical

199 We assessed the ability of the histone deacetylase inhibitor panobinostat to disrupt HI

200 organotypic cultures with trichostatin A, a histone deacetylase inhibitor, partially restored differ

201 Treatment with trichostatin A, but not other histone deacetylase inhibitors, partially restored reeli

202 r of small molecules, we have found that the histone deacetylase inhibitor phenylbutyrate increases D

203 how the effector molecule HC-toxin (HCT), a histone deacetylase inhibitor produced by the fungal pat

204 with TEPP-46 and shikonin or treatment with histone deacetylase inhibitors produced similar results.

205 ibitors, and cell culture in the presence of histone deacetylase inhibitors, promote development to t

206 hput sequencing (ATAC-seq), we show that the histone deacetylase inhibitor promotes accessibility at

207 e further amplified by DNA demethylation and histone deacetylase inhibitors providing an exquisite th

208 amine-based Pt(IV) derivative containing the histone deacetylase inhibitor rac-2-(2-propynyl)octanoat

209 f REST was blocked by cycloheximide; and (c) histone deacetylase inhibitors reactivated the WT parent

210 lly, growth of Salmonella in the presence of histone deacetylases inhibitors reduced expression of SP

211 Romidepsin (RMD) is a histone deacetylase inhibitor reported to reverse HIV-1

212 Treatment with histone deacetylase inhibitors rescued IR-induced ATM si

213 ecitabine (demethylating agent) or butyrate (histone deacetylase inhibitor) restored hOCT1 expression

214 Histone deacetylase inhibitors reversed the effects of c

215 ombination with bromodomain inhibitor JQ1 or histone deacetylase inhibitors robustly induce HIV-1 tra

216 Administration of the histone deacetylase inhibitor SAHA (suberoylanilide hydr

217 and Drug Administration-approved anticancer histone deacetylase inhibitor, SAHA, reduces myocardial

218 ns using a combination of the checkpoint and histone deacetylase inhibitors.See related article by Fu

219 ion in aging and AD models and suggests that histone deacetylase inhibitors should be further explore

220 DNA methyltransferase and histone deacetylase inhibitors similarly reset the trans

221 dial prefrontal cortex administration of the histone deacetylase inhibitor sodium butyrate (NaB) afte

222 In particular, the histone deacetylase inhibitor sodium butyrate (SB) may i

223 inhibitor N-omega-hydroxy-l-norarginine and histone deacetylase inhibitor sodium valproate.

224 ting pair-bond regulation and found that the histone deacetylase inhibitors sodium butyrate and trich

225 C, we studied the effect of the FDA-approved histone deacetylase inhibitor suberanilohydroxamic acid

226 e and resveratrol) and were increased by the histone deacetylase inhibitor, suberolylanilide hydroxam

227 (Dznep) either alone or in combination with histone deacetylase inhibitor suberoylanilide hydroxamic

228 cal studies of in vivo administration of the histone deacetylase inhibitor suberoylanilide hydroxamic

229 ow that the chromatin opening induced by the histone deacetylase inhibitor suberoylanilide hydroxamic

230 that treatment with epigenetic therapy, the histone deacetylase inhibitor suberoylanilide hydroxamic

231 Degradation of Dnmt1 by the histone deacetylase inhibitor suberoylanilide hydroxamic

232 olecules, both of which were reversed by the histone deacetylase inhibitor suberoylanilide hydroxanic

233 orated in mice treated with the FDA-approved histone deacetylase inhibitor, suberoylanilide hydroxami

234 Although histone deacetylase inhibitors such as suberoylanilide h

235 In particular, our results with histone deacetylase inhibitors support the view that chr

236 ression induced by LAC, whereas the use of a histone deacetylase inhibitor supported the epigenetic c

237 Combined treatment with MAPK-pathway and histone-deacetylase inhibitors suppressed MITF expressio

238 ethyltransferase inhibitor decitabine or the histone deacetylase inhibitor tacedinaline on NET cells

239 While butyrate is a known histone deacetylase inhibitor that activates expression

240 Vorinostat is a histone deacetylase inhibitor that changes gene expressi

241 Entinostat is a histone deacetylase inhibitor that has been combined wit

242 in Cpt2M(-/-) hearts, but trichostatin A, a histone deacetylase inhibitor that improves cardiac remo

243 Modulation of chromatin conformation using a histone deacetylase inhibitor that increases transcripti

244 Pretreatment with trichostatin A, a pan-histone deacetylase inhibitor that renders chromatin dec

245 A histone deacetylase inhibitor that suppresses neurodegen

246 Entinostat is an oral isoform selective histone deacetylase inhibitor that targets resistance to

247 Moreover, valproic acid, a histone deacetylase inhibitor that we previously showed

248 Histone deacetylase inhibitors that increased the acetyl

249 ignature-relevant drug candidates, including histone deacetylase inhibitors that specifically reduced

250 ted with both calcitriol and trichostatin A (histone deacetylase inhibitor), the level of IL-9 reache

251 ic assessments of response and resistance to histone deacetylase inhibitor therapy.

252 Treatment of mammalian cells with histone deacetylase inhibitors to increase euchromatin o

253 Histone deacetylase inhibitor treatment significantly re

254 that all functional NKG2D ligands induced by histone deacetylase inhibitor treatment were abolished b

255 ivation of HDAC9 expression and sensitive to histone deacetylase inhibitor treatment.

256 inhibited surface expression of MICA/B after histone deacetylase inhibitor treatment; the inhibition

257 intensity in the nucleus increased following histone-deacetylase inhibitor treatment.

258 nsferase inhibitor 5-Aza 2-deoxycytidine and histone deacetylase inhibitor trichostatin A (herein ref

259 ces of acute intra-CA1 administration of the histone deacetylase inhibitor Trichostatin A (TSA) on cu

260 a combination regimen of bortezomib and the histone deacetylase inhibitor trichostatin A abolished H

261 of skin repair we found that the class I-IIa histone deacetylase inhibitor trichostatin A accelerated

262 t did inhibit the relaxation produced by the histone deacetylase inhibitor trichostatin A, an effect

263 n agent 5'-aza-2'-deoxycytidine, but not the histone deacetylase inhibitor trichostatin A, drasticall

264 trodifferentiation process is blocked by the histone deacetylase inhibitor trichostatin A, opening ne

265 versal of endotoxin tolerance exerted by the histone deacetylase inhibitor trichostatin A.

266 (THLE-2 and THLE-3) were incubated with the histone deacetylase inhibitor trichostatin A.

267 ration and angiogenesis were reversed by the histone deacetylase inhibitor trichostatin A.

268 (SIRT) inhibitor nicotinamide but not by the histone deacetylase inhibitor trichostatin A.

269 IGF-1(NEG) and mIGF-1(POS) SMA mice with the histone deacetylase inhibitor, trichostatin A (TSA), res

270 When treated with the histone deacetylase inhibitor, Trichostatin A, genes nea

271 eased the sensitivity of cancer cells to the histone deacetylase inhibitor, trichostatin A, in C42B,

272 anti-microtubule drug thiabendazole and the histone deacetylase inhibitor tricostatin A when a histo

273 Treatment of cells with phorbol ester or histone deacetylase inhibitors triggered the expression

274 A histone deacetylase inhibitor, TSA, stimulated Rgs16::GF

275 (3C) consisting of sodium butyrate (a broad histone deacetylase inhibitor), UNC0646 (a histone methy

276 ormal cells, by DNA-demethylating agents and histone deacetylase inhibitors using clinically achievab

277 conducted to investigate the effects of the histone deacetylase inhibitor valproate and all-trans re

278 uciferase activity assay, we found that both histone deacetylase inhibitor valproic acid (VPA) and DN

279 The histone deacetylase inhibitor valproic acid (VPA) is kno

280 vated levels of hTdp1 were more sensitive to histone deacetylase inhibitors valproic acid (VPA) and t

281 We show that histone deacetylase inhibitors valproic acid and butyrat

282 th all-trans retinoic acid combined with the histone-deacetylase inhibitor valproic acid.

283 tion is further promoted by treatment with a histone deacetylase inhibitor, valproic acid (VPA).

284 Importantly, the histone deacetylase inhibitor, valproic acid, blocked ME

285 d) obtained by conjugation to valproic acid (histone deacetylase inhibitor) via an ester bond, exhibi

286 gated the mechanism of MMP-13 suppression by histone deacetylase inhibitor vorinostat (SAHA).

287 o receive ART-only (control) or ART plus the histone deacetylase inhibitor vorinostat (the kick) and

288 A single dose of the histone deacetylase inhibitor vorinostat (VOR) up-regula

289 We performed two phase I trials of the histone deacetylase inhibitor vorinostat combined with e

290 n the present study, we demonstrate that the histone deacetylase inhibitor vorinostat not only reprog

291 al administration of the clinically approved histone deacetylase inhibitor vorinostat not only restor

292 lowed to devise an inactive precursor of the histone deacetylase inhibitor vorinostat that was effici

293 Notably, combining the histone deacetylase inhibitor vorinostat with a PI3K inh

294 Epigenetic modifiers, including the histone deacetylase inhibitor vorinostat, may sensitize

295 nergistically increased upon exposure to the histone deacetylase inhibitor vorinostat.

296 Combining a demethylation agent and a histone deacetylase inhibitor was sufficient to reexpres

297 As a class, histone deacetylase inhibitors were greatly overrepresen

298 Histone deacetylase inhibitors were used to treat cells.

299 vity relationship for designing novel potent histone deacetylase inhibitors, which can be applied tow

300 nsin-converting enzyme (ACE) inhibitor and a histone deacetylase inhibitor would maximally reverse th